1286738-88-2

Upstream product

• 16153-81-4 4-(4-Methyl-piperazino)-anilin 
• 16155-03-6 1-methyl-4-(4-nitrophenyl)piperazine 
• 109-01-3 1-methyl-piperazine 
• 100-00-5 4-chlorobenzonitrile 
• 1232030-40-8 6-bromo-8-ethyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1286738-62-2 6-bromo-8-ethyl-2-methanesulfinyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1232030-55-5 6-bromo-8-ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one 
• 352328-87-1 6-bromo-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 211244-81-4 2-methanesulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1352130-67-6 6-(2-chloro-4-methanesulfonyl-phenyl)-8-ethyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1286738-87-1 C₂₈H₂₈N₆OS₂ 

Relevant academic research and scientific papers

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disoders.